Company & Sponsor Intelligence
Northwell Health
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials7
Recruiting1
Completed4
Countries1
Therapeutic footprint
adhdalzheimersepilepsyparkinsonsschizophrenia
Indexed studies
NCT00169949Aripiprazole Treatment of the Prodrome
schizophrenia · United StatesNA
schizophrenia · United StatesNA
NCT018447001/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain
schizophrenia · United StatesPHASE4
schizophrenia · United StatesPHASE4
NCT04721691Efficacy of Epidiolex in Patients With Electrical Status Epilepticus of Sleep (ESES).
epilepsy · United StatesPHASE1
epilepsy · United StatesPHASE1
NCT04228172Genotypic Influences on Network Progression in Parkinson's Disease
parkinsons · United StatesACTIVE_NOT_RECRUITING
parkinsons · United StatesACTIVE_NOT_RECRUITING
NCT06801912A BCT Intervention for an Hourly Activity Habit Among Caregivers for Persons With AD/ADRD
alzheimers · United StatesNA
alzheimers · United StatesNA
NCT06803797BCT Intervention For Walking Habit Among Caregivers of People With AD/ADRD
alzheimers · United StatesNA
alzheimers · United StatesNA
NCT05588505Cognitive-Behavioral Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in College Students - Study 1
adhd · United StatesNA
adhd · United StatesNA
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →